ABT fell 4.6% to around $96, breaking below its 20‑day moving average and testing support at $94. The $21 B acquisition, while strategic, prompted a profit‑forecast cut, making the near‑term outlook neutral.

Investors reacted sharply to the profit‑forecast downgrade, driving sentiment bearish despite the broader market rally. The health‑care sector weakness reinforces short‑term downside pressure on ABT.

The forecast reduction raises risk on earnings volatility, but the sizable deal expands pipeline and medium‑term revenue visibility, keeping a bullish long‑term view. Maintain exposure but monitor execution risk.

Technical indicators show ABT’s RSI at 28, suggesting oversold conditions, while the price is forming a potential bullish reversal pattern near the 50‑day MA. Data implies a rebound could be imminent if volume supports.